P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility

BMC Genetics

Haowei Xue¹  Ming Sun¹  Yukun Hu¹  Ling Zhu¹  Wenyu Yang³  Yin Lou⁶  Song Wu⁵  Wei Hou²  Ying Gu⁴  Jun Hou¹ 

[1] Department of Stomatology, the First Affiliated Hospital of the Anhui Medical University, Hefei 230032, Anhui, China;Department of Preventive Medicine, School of Medicine, Stony Brook University, Stony Brook 11794, NY, USA;Department of Stomatology, the Second Affiliated Hospital of the Anhui Medical University, Hefei 23061, Anhui, China;Department of General Dentistry, School of Dental Medicine, Stony Brook University, Stony Brook 11794, NY, USA;Department of Applied Mathematics Statistics, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook 11794, NY, USA;Department of Orthopaedic Surgery, the Second Affiliated Hospital of the Anhui Medical University, Hefei 230601, Anhui, China

关键词: Meta-analysis;    Susceptibility;    Polymorphism;    Oral cancer;    Human papillomavirus;    P53 codon 72;   

Others  :  1218922
DOI  :  10.1186/s12863-015-0235-7

 received in 2014-09-30, accepted in 2015-06-17,  发布年份 2015

【 摘 要 】

Background

Tumor suppressor gene p53 plays an important role in the maintenance of the genomic integrity, and mutation in the gene may alter an individual’s susceptibility to various carcinomas. P53 Arg72Pro or codon 72 polymorphism has been indicated to increase the risk of developing certain cancers such as bladder cancer and cervical cancer. Human papillomavirus (HPV) infection has been shown as a risk factor for certain cancers such as cervical cancer and oral cancer as well, and the HPV oncoprotein E6 may induce the degradation of p53 function. However, the association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection remains inconclusive. Therefore, this meta-analysis involving 5,614 participants was performed to investigate the relations among the p53 Arg72Pro polymorphism, HPV infection, and the risk of developing oral cancer.

Results

A search of the literature by PubMed, Embase, Web of Science, and China National Knowledge Infrastructure databases was conducted to identify studies based on the inclusion and exclusion criteria. Odds ratios with 95 % confidence intervals were combined using a random-effect model or a fixed-effect model. The current study was conducted with 13 studies consisting of 2,413 cases and 3,201 controls. Neither overall analysis nor stratified analyses detected any obvious evidence of association between p53 Arg72Pro polymorphism and oral cancer susceptibility in all genetic models. However, a significant association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection was detected in the Arg/Arg vs. Arg/Pro + Pro/Pro model.

Conclusion

In the current meta-analysis which used the quantitative data synthesis for the first time, our study demonstrated that p53 Arg72Pro polymorphism together with HPV infection might jointly alter an individual’s susceptibility to the risk of oral cancer. Our results suggested that p53 Arg72Pro polymorphism may partly contribute to the pathogenesis of oral cancer development.

【 授权许可】

   
2015 Hou et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int. 2011; 2011:431246.
• [2]Petersen PE. Oral cancer prevention and control—the approach of the World Health Organization. Oral Oncol. 2009; 45:454-460.
• [3]Zain RB, Ikeda N, Gupta PC, Warnakulasuriya S, van Wyk CW, Shrestha P, Axéll T. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25–27, 1996. J Oral Pathol Med. 1999; 28:1-4.
• [4]Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002; 21:7435-7451.
• [5]Zhong Y, Carmella SG, Upadhyaya P, Hochalter JB, Rauch D, Oliver A, Jensen J, Hatsukami D, Wang J, Zimmerman C, Hecht SS. Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides. Chem Res Toxicol. 2011; 24:246-252.
• [6]Enwonwu CO, Meeks VI. Bionutrition and oral cancer in humans. Crit Rev Oral Biol Med. 1995; 6:5-17.
• [7]Scully C, Bedi R. Ethnicity and oral cancer. Lancet Oncol. 2000; 1:37-42.
• [8]Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88:323-331.
• [9]Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1993; 1155:181-205.
• [10]Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011; 2011:978312.
• [11]Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992; 71:587-597.
• [12]Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay H, Amir E, Liu G. p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012; 18:6407-15.
• [13]Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human papillomavirus and risk of oral cancer. Laryngoscope. 1998; 108:1098-1103.
• [14]Portugal LG, Goldenberg JD, Wenig BL, Ferrer KT, Nodzenski E, Sabnani JB, Javier C, Weichselbaum RR, Vokes EE. Human papillomavirus expression and p53 gene mutations in squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1997; 123:1230-1234.
• [15]Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63:1129-1136.
• [16]Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248:76-79.
• [17]Huibregtse JM, Scheffner M, Howley PM. Acellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991; 10:4129-4135.
• [18]Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature. 1998; 393:229-234.
• [19]Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou Q, Wei Q, Li G. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 2012; 131:E251-8.
• [20]Ji X, Neumann AS, Sturgis EM, Adler-Storthz K, Dahlstrom KR, Schiller JT, Wei Q, Li G. p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. Carcinogenesis. 2008; 29:875-879.
• [21]Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP. p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90:334-339.
• [22]Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10:101-102.
• [23]Higgins JP, Thompson SE. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539-1558.
• [24]DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
• [25]Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719-748.
• [26]Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-1101.
• [27]Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.
• [28]Patel KR, Vajaria BN, Begum R, Shah FD, Patel JB, Shukla SN, Patel PS. Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, West India. Asian Pac J Cancer Prev. 2013; 14:1093-1100.
• [29]Kuroda Y, Nakao H, Ikemura K, Katoh T. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol. 2007; 43:1043-1048.
• [30]Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A. Association of P53 codon 72 polymorphism and ameloblastoma. Oral Dis. 2010; 16:631-635.
• [31]Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008; 29:2120-2125.
• [32]Zemleduch T, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodziński PP. Contribution of polymorphism in codon 72 of TP53 gene to laryngeal cancer in Polish patients. Oral Oncol. 2009; 45:683-686.
• [33]Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC, Kapur S, Saxena S. Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol. 2011; 30:163-171.
• [34]Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 2008; 87:243-252.
• [35]Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog. 2009; 48:790-800.
• [36]Lin YC, Huang HI, Wang LH, Tsai CC, Lung O, Dai CY, Yu ML, Ho CK, Chen CH. Polymorphisms of COX-2 -765G > C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008; 44:798-804.
• [37]Saini R, Tang TH, Zain RB, Cheong SC, Musa KI, Saini D, Ismail AR, Abraham MT, Mustafa WM, Santhanam J. Significant association of high-risk human papillomavirus (HPV) but not of p53 polymorphisms with oral squamous cell carcinomas in Malaysia. J Cancer Res Clin Oncol. 2011; 137:311-320.
• [38]de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324:17-27.